Epigenetic approaches for cervical neoplasia screening (Review).
DNA methylation
cervical cancer
cervical screening
epigenetics
human papillomavirus
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
23
06
2021
accepted:
27
09
2021
entrez:
12
11
2021
pubmed:
13
11
2021
medline:
13
11
2021
Statut:
ppublish
Résumé
Human papillomavirus (HPV) infection is the leading cause of cervical cancer. The Papanicolaou cytology test is the usually employed type of screening for this infection; however, its sensibility is limited. Only a small percentage of women infected with high-risk HPV develop cervical cancer with an array of genetic and epigenetic modifications. Thus, it is necessary to develop rapid, reproducible and minimally invasive technologies for screening. DNA methylation has gained attention as an alternative method for molecular diagnosis and prognosis in HPV infection. The aim of the present review was to highlight the potential of DNA methylation in cervical neoplasia screening for clinical applications. It was observed that the methylation human and viral genes was correlated with high-grade lesions and cancer. Methylation biomarkers have shown a good capacity to discriminate between high-grade lesions with a transformative potential and cervical cancer, being able to detect these modifications at an early stage. With further research, the epigenetic profiles and subtypes of the tumors could be elaborated, which would aid in therapy selection by opening avenues in personalized precision medicine. Response to therapy could also be evaluated through such methods and the accessibility of liquid biopsies would allow a constant monitoring of the patient's status without invasive sampling techniques.
Identifiants
pubmed: 34765022
doi: 10.3892/etm.2021.10916
pii: ETM-22-6-10916
pmc: PMC8576616
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1481Informations de copyright
Copyright: © Albulescu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Clin Cancer Res. 2013 Oct 1;19(19):5444-55
pubmed: 23894057
Oncotarget. 2016 Dec 6;7(49):81255-81267
pubmed: 27835605
Dis Markers. 2017;2017:7243968
pubmed: 28634418
Nat Commun. 2018 Dec 4;9(1):4915
pubmed: 30514834
J Int AIDS Soc. 2018 Aug;21(8):e25165
pubmed: 30101434
EMBO J. 1999 Sep 15;18(18):5061-72
pubmed: 10487758
Brief Funct Genomics. 2016 Nov;15(6):491-500
pubmed: 27288434
Urology. 2019 Jun;128:62-65
pubmed: 29660369
BJU Int. 2019 Jun;123(6):959-967
pubmed: 30653818
Nat Rev Mol Cell Biol. 2015 Sep;16(9):519-32
pubmed: 26296162
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):
pubmed: 27194046
Oncotarget. 2017 Jul 22;8(37):62274-62285
pubmed: 28977944
J Virol. 2019 Apr 3;93(8):
pubmed: 30728257
Nat Rev Genet. 2012 Apr 03;13(5):343-57
pubmed: 22473383
Epigenetics. 2018;13(7):769-778
pubmed: 30079796
Sci Rep. 2015 Jul 08;5:11724
pubmed: 26152361
EBioMedicine. 2018 Apr;30:138-147
pubmed: 29627389
Oncogene. 2007 Mar 8;26(11):1650-5
pubmed: 16983344
Front Genet. 2019 Nov 14;10:1150
pubmed: 31803237
Int J Mol Sci. 2018 Jun 08;19(6):
pubmed: 29890655
Expert Rev Mol Diagn. 2014 Apr;14(3):293-305
pubmed: 24649818
Clin Epigenetics. 2017 Jan 31;9:8
pubmed: 28163793
Int J Gynecol Cancer. 2012 Nov;22(9):1557-63
pubmed: 23095774
Int J Cancer. 2017 Aug 15;141(4):701-710
pubmed: 28500655
PLoS Pathog. 2021 Aug 25;17(8):e1009875
pubmed: 34432858
Eur Urol Oncol. 2018 Sep;1(4):307-313
pubmed: 31100252
Genes (Basel). 2019 Jan 09;10(1):
pubmed: 30634483
Onco Targets Ther. 2017 Feb 16;10:945-953
pubmed: 28243130
Cochrane Database Syst Rev. 2017 Aug 10;8:CD008587
pubmed: 28796882
Mol Cell. 2010 Jun 11;38(5):700-11
pubmed: 20542002
Adv Urol. 2012;2012:503271
pubmed: 22761614
Tumour Biol. 2014 Jun;35(6):5083-93
pubmed: 24554414
J Urol. 2017 Mar;197(3 Pt 1):590-595
pubmed: 27746284
Int J Genomics. 2018 Apr 16;2018:8260652
pubmed: 29850477
CA Cancer J Clin. 2012 May-Jun;62(3):147-72
pubmed: 22422631
Carcinogenesis. 2010 May;31(5):918-26
pubmed: 20123756
Mol Cell. 2005 Jan 21;17(2):251-64
pubmed: 15664194
J Virol. 2002 Sep;76(17):8710-21
pubmed: 12163591
Life (Basel). 2021 Apr 30;11(5):
pubmed: 33946400
BMC Cancer. 2018 Dec 3;18(1):1197
pubmed: 30509219
Future Microbiol. 2011 Sep;6(9):1083-98
pubmed: 21958146
Mol Carcinog. 2018 Mar;57(3):370-382
pubmed: 29077234
EMBO J. 2005 May 18;24(10):1821-30
pubmed: 15861133
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:36-50
pubmed: 28528689
Clin Cancer Res. 2014 Apr 1;20(7):1978-89
pubmed: 24691641
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
pubmed: 24591631
EMBO Rep. 2011 Dec 23;13(1):28-35
pubmed: 22157888
Lab Med. 2018 Mar 21;49(2):97-111
pubmed: 29378033
J Virol. 2010 May;84(10):5212-21
pubmed: 20219920
Gynecol Oncol. 2009 Feb;112(2):293-9
pubmed: 19054549
J Cell Biochem. 2020 Mar;121(3):2713-2724
pubmed: 31680300
BMC Genomics. 2010 Dec 14;11:701
pubmed: 21156036
BMC Genomics. 2008 Feb 04;9:64
pubmed: 18248679
Cell Res. 2011 Mar;21(3):381-95
pubmed: 21321607
Methods Mol Biol. 2012;863:67-109
pubmed: 22359288
Sci Rep. 2019 Feb 28;9(1):3088
pubmed: 30816167
Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):437-446
pubmed: 30343277
Int J Cancer. 2017 Mar 1;140(5):1119-1133
pubmed: 27874187
J Gynecol Oncol. 2017 Jul;28(4):e56
pubmed: 28541643
Technol Cancer Res Treat. 2019 Jan 1;18:1533033818821421
pubmed: 30760122
Mol Med Rep. 2011 Jan-Feb;4(1):121-8
pubmed: 21461574
Pathogens. 2020 Jun 18;9(6):
pubmed: 32570816
Oncogene. 2012 May 3;31(18):2335-49
pubmed: 21963854
Clin Epigenetics. 2020 Nov 11;12(1):171
pubmed: 33176878
Oncogene. 2003 Jun 19;22(25):3833-41
pubmed: 12813456
Epigenomics. 2009 Dec;1(2):239-59
pubmed: 20495664
J Virol. 2004 Apr;78(7):3533-41
pubmed: 15016876
Exp Mol Pathol. 2019 Feb;106:7-16
pubmed: 30471246
Lancet. 2011 Nov 26;378(9806):1868-73
pubmed: 22051739
J Med Oncol Ther. 2016;1(2):34-40
pubmed: 28149961
Int J Gynecol Pathol. 2002 Apr;21(2):198-202
pubmed: 11917233
Curr Mol Med. 2010 Mar;10(2):123-32
pubmed: 20196733
Am J Cancer Res. 2020 Jul 01;10(7):1954-1978
pubmed: 32774995
J Clin Virol. 2016 Mar;76 Suppl 1:S49-S55
pubmed: 26643050
Virol J. 2016 Apr 05;13:60
pubmed: 27044426
Papillomavirus Res. 2016 Dec;2:85-88
pubmed: 29074190
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
J Thorac Oncol. 2017 Jan;12(1):77-84
pubmed: 27544059
Clin Epigenetics. 2016 Nov 18;8:120
pubmed: 27891193
J Cancer. 2019 Aug 7;10(19):4588-4595
pubmed: 31528222
Clin Epigenetics. 2016 Jun 10;8:66
pubmed: 27293491
Int J Cancer. 2014 Sep 15;135(6):1425-32
pubmed: 24535756
Oncol Lett. 2018 Jan;15(1):11-22
pubmed: 29285184
JAMA. 2019 May 28;321(20):2018-2019
pubmed: 31135834
BMJ. 2008 Oct 13;337:a1754
pubmed: 18852164
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Singapore Med J. 2015 Oct;56(10):586-7
pubmed: 26512152
Oncol Rep. 2010 Dec;24(6):1599-604
pubmed: 21042757
RNA. 2009 Apr;15(4):637-47
pubmed: 19258450
Methods Mol Biol. 2015;1238:3-25
pubmed: 25421652
Oncogene. 2003 Sep 11;22(39):7871-81
pubmed: 12970734
EMBO J. 1999 May 4;18(9):2449-58
pubmed: 10228159
J Immunoassay Immunochem. 2019;40(1):81-90
pubmed: 30518287
Virology. 2014 Jan 5;448:314-21
pubmed: 24314662
Eur J Cancer. 2007 Jul;43(11):1679-86
pubmed: 17601725
N Engl J Med. 2014 Apr 3;370(14):1287-97
pubmed: 24645800
Int J Cancer. 2016 Jun 1;138(11):2745-51
pubmed: 26790008
Biochim Biophys Acta. 2012 Feb;1822(2):248-60
pubmed: 22001440
Biomed Pharmacother. 2018 Jun;102:242-248
pubmed: 29567536
Clin Epigenetics. 2020 Apr 21;12(1):57
pubmed: 32317020
N Engl J Med. 2001 May 24;344(21):1603-7
pubmed: 11372013
Cancer Biomark. 2019;25(1):53-65
pubmed: 31006665
Clin Genet. 2012 Apr;81(4):303-11
pubmed: 22082348
Mol Clin Oncol. 2015 Jul;3(4):851-858
pubmed: 26171195
Clin Epigenetics. 2020 Jun 23;12(1):91
pubmed: 32576279
Subcell Biochem. 2013;61:289-317
pubmed: 23150256
Acta Cytol. 2016;60(6):501-512
pubmed: 27806357
Oncol Res Treat. 2014;37 Suppl 3:48-57
pubmed: 25195832
Exp Ther Med. 2013 Nov;6(5):1332-1336
pubmed: 24223668
J Virol. 2004 Nov;78(21):11451-60
pubmed: 15479788
Clin Lab. 2017 Feb 1;63(2):335-340
pubmed: 28182350
Cancer Cell Int. 2019 Jul 8;19:175
pubmed: 31320837
Carcinogenesis. 2012 Jul;33(7):1286-93
pubmed: 22552403
J Transl Med. 2011 Jun 08;9:86
pubmed: 21651777
Cancer Biomark. 2015;15(5):669-75
pubmed: 26406956
Cell Oncol (Dordr). 2014 Aug;37(4):297-303
pubmed: 25123395
J Oral Pathol Med. 2020 Aug;49(7):636-644
pubmed: 31981240
Int J Gynecol Cancer. 2014 Jun;24(5):928-34
pubmed: 24844223
Clin Epigenetics. 2019 Oct 12;11(1):140
pubmed: 31606044
Mol Cancer. 2020 Apr 27;19(1):79
pubmed: 32340605
Adv Exp Med Biol. 2013;754:3-29
pubmed: 22956494
Lancet Oncol. 2016 Oct;17(10):1386-1395
pubmed: 27575023
Front Oncol. 2019 Dec 03;9:1281
pubmed: 31850197
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2130-5
pubmed: 21245294
Nature. 2015 Jan 15;517(7534):321-6
pubmed: 25592537
Clin Cancer Res. 2018 May 1;24(9):2194-2202
pubmed: 29420222